Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy

Area of Science:

• Pediatric Orthopedics
• Neuromuscular Disorders
• Rehabilitation Medicine

Background:

• Spastic cerebral palsy (CP) significantly impacts children's motor function and gait.
• Multilevel interventions are crucial for managing CP, with botulinum toxin type A (BTX-A) being a key component.
• Understanding the long-term effects of BTX-A on gait is essential for optimizing treatment strategies.

Purpose of the Study:

• To evaluate the long-term effects of multilevel botulinum toxin type A (BTX-A) treatments on the gait patterns of children with spastic cerebral palsy (CP).
• To compare gait parameters between children with CP treated with BTX-A and those receiving standard care without BTX-A.

Main Methods:

• A nested case-control study involving 30 children with spastic CP (GMFCS Levels I-III) who received BTX-A injections as part of their treatment.
• A matched control group of 30 children with spastic CP received identical treatment but without BTX-A.
• Three-dimensional gait analysis was performed at a mean of 1 year 10 months post-treatment to assess motor development and gait patterns.

Main Results:

• The BTX-A group exhibited a significantly less pathological gait pattern compared to the control group.
• Key differences included improved pelvic anterior tilt, maximum hip and knee extension, and internal hip rotation in the BTX-A group.
• These findings suggest a prolonged positive effect of BTX-A on gait parameters.

Conclusions:

• Multilevel BTX-A injections, when combined with conservative treatments, lead to improved gait patterns in children with spastic CP.
• BTX-A treatment helps mitigate secondary gait problems, potentially reducing the need for complex surgeries later in life.
• This approach enhances long-term quality of life for children with CP by improving their motor function.